STOCK TITAN

REGENXBIO Inc. - $RGNX STOCK NEWS

Welcome to our dedicated page for REGENXBIO news (Ticker: $RGNX), a resource for investors and traders seeking the latest updates and insights on REGENXBIO stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REGENXBIO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REGENXBIO's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
REGENXBIO Inc.

Nasdaq:RGNX

RGNX Rankings

RGNX Stock Data

825.39M
37.36M
7.18%
81.62%
8.05%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ROCKVILLE

About RGNX

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.